International Journal of Neuropsychopharmacology最新文献

筛选
英文 中文
Frequent Vocalizations and DBS-Responsive Hyperkinesia in a Striatal Disinhibition Rat Model for Tourette Syndrome. 图雷特综合征纹状体去抑制大鼠模型中的频繁发声和dbs反应性运动亢进。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-13 DOI: 10.1093/ijnp/pyaf039
Boriss Sagalajev, Lina Lennartz, Niloofar Mokhtari, Mikolaj Szpak, Meryem Sinem Uyar, Thomas Schüller, Juan Carlos Baldermann, Pablo Andrade, Veerle Visser-Vandewalle, Thibaut Sesia
{"title":"Frequent Vocalizations and DBS-Responsive Hyperkinesia in a Striatal Disinhibition Rat Model for Tourette Syndrome.","authors":"Boriss Sagalajev, Lina Lennartz, Niloofar Mokhtari, Mikolaj Szpak, Meryem Sinem Uyar, Thomas Schüller, Juan Carlos Baldermann, Pablo Andrade, Veerle Visser-Vandewalle, Thibaut Sesia","doi":"10.1093/ijnp/pyaf039","DOIUrl":"https://doi.org/10.1093/ijnp/pyaf039","url":null,"abstract":"<p><strong>Background: </strong>The lack of a rodent model for both motor and phonic tics hinders research on deep brain stimulation (DBS) for refractory Tourette syndrome (TS). Striatal disinhibition with a GABA-A antagonist (bicuculline) was previously shown to induce hyperkinesia and vocalizations in monkeys, indicating its potential as a TS model. In rats, however, only hyperkinesia was validated, prompting us to investigate whether they can also develop abnormal vocalizations and whether both conditions respond to thalamic DBS.</p><p><strong>Methods: </strong>Rats underwent surgical implantation of a unilateral guide cannula targeting the caudate putamen (CPu) or nucleus accumbens (NAc). Additionally, they were implanted with an ipsilateral stimulation electrode targeting the border between the central medial (CM) and ventrolateral (VL) thalamic nuclei. Motor changes and ultrasound vocalizations were recorded and characterized offline.</p><p><strong>Results: </strong>CPu bicuculline elicited arrhythmic shoulder jerks that tend to appear in fading bursts and sporadically alternate with sustained generalized hyperextension. NAc bicuculline elicited similar hyperkinesia, but at a much lower dose to prevent convulsions. DBS of CM/VL, but not adjacent regions, attenuated hyperkinesia with lower intensity showing stronger effects. In addition, bicuculline in NAc, but not CPu, elicited nonsensical vocalizations. However, the effect of CM/VL DBS on vocalizations remained inconclusive.</p><p><strong>Conclusions: </strong>Hyperkinesia temporal features, co-development with vocalizations, and responsiveness to CM/VL DBS suggest striatal disinhibition may serve as a TS rat model. Yet, other movement disorders with vocal complications cannot be excluded, given the challenge of validating key tic indicators in animals, such as premonitory urge and suppressibility.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Influence of Synaptic Density and Anxiety on Pain Perception: Evidence from a [11C]UCB-J PET Imaging Study. 探讨突触密度和焦虑对疼痛感知的影响:来自UCB-J PET成像研究的证据[11]。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-13 DOI: 10.1093/ijnp/pyaf040
Karina Moisieienko, Ruth H Asch, Margaret T Davis, Robert H Pietrzak, Irina Esterlis
{"title":"Exploring the Influence of Synaptic Density and Anxiety on Pain Perception: Evidence from a [11C]UCB-J PET Imaging Study.","authors":"Karina Moisieienko, Ruth H Asch, Margaret T Davis, Robert H Pietrzak, Irina Esterlis","doi":"10.1093/ijnp/pyaf040","DOIUrl":"https://doi.org/10.1093/ijnp/pyaf040","url":null,"abstract":"<p><strong>Background: </strong>Structural and functional brain alterations may be associated with pain and anxiety. We hypothesized that synaptic density (measured in vivo with [11C]UCB-J and positron emission tomography quantification of synaptic vesicle SV2A) alterations may play a role in higher pain sensitivity, and that this relationship may be mediated by anxiety symptoms.</p><p><strong>Methods: </strong>Twenty-one mentally and medically healthy subjects (11 males, 10 females; age 45.1 ± 16.9 years) participated in imaging, acute pain [cold pressor test (CPT)] and anxiety (State-Trait Anxiety Inventory) assessments. SV2A density was quantified as regional volumes of distribution (VT) using a one-tissue compartment model with a plasma input function. SV2A density was assessed in five regions of interest (ROIs) that were previously shown to be associated with pain: dorsolateral prefrontal cortex (DLPFC), amygdala, anterior cingulate cortex (ACC), fusiform gyrus, and cerebellum.</p><p><strong>Results: </strong>State anxiety was positively correlated with pain sensitivity (r = 0.60, p=.004). Significant negative correlations were observed between pain sensitivity and SV2A density in cerebellum (r = -0.67, p=.001), fusiform gyrus (r = -0.66, p=.001), DLPFC (r = -0.63, p=.002), and ACC (r = -0.58, p=.006). Mediation analysis revealed a significant indirect effect of cerebellar synaptic density on pain sensitivity through state anxiety symptoms (B = -0.77, 95% CI [-1.89, -0.04]), accounting for 33% of the total effect. For the fusiform gyrus, the direct effect on pain sensitivity remained significant after controlling for anxiety symptoms (B = -1.67, p=.020), while the indirect effect through anxiety symptoms was not significant (B = -0.43, 95% CI [-1.44, 0.37]).</p><p><strong>Conclusion: </strong>Results provide the first known in vivo evidence that lower synaptic (SV2A) density is associated with greater pain sensitivity, particularly in the fusiform gyrus and cerebellum. Mediation analyses revealed that state anxiety partially mediated the relationship between cerebellar synaptic density and pain sensitivity, while having an additive - but not mediating - effect on the relationship between fusiform synaptic density and pain sensitivity.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice. 内源性血清素在小鼠裸盖菇素致幻作用中的作用。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf035
Ines Erkizia-Santamaría, Nerea Martínez-Álvarez, Leyre Salinas-Novoa, Jose Javier Meana, Jorge Emilio Ortega
{"title":"Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice.","authors":"Ines Erkizia-Santamaría, Nerea Martínez-Álvarez, Leyre Salinas-Novoa, Jose Javier Meana, Jorge Emilio Ortega","doi":"10.1093/ijnp/pyaf035","DOIUrl":"10.1093/ijnp/pyaf035","url":null,"abstract":"<p><strong>Background: </strong>The psychedelic psilocybin has been posited as efficacious for the treatment of depression. However, the potential link between the intensity of acute psychedelic effects and long-term therapeutic outcomes remains undiscovered. Moreover, the impact of classical antidepressant drugs that modulate serotonergic activity on psilocybin's effects is a clinically relevant concern. The aim of the present study was to assess serotonergic mechanisms implicated in the regulation of the intensity of the psilocybin-induced acute effects.</p><p><strong>Methods: </strong>The head-twitch response (HTR), the most translational behavioral assay to characterize the psychedelic-like effect in rodents was performed. Moreover, the role of endogenous serotonin (5-HT) on psilocybin-induced HTR was studied by in vivo brain microdialysis technique.</p><p><strong>Results: </strong>Maximally effective psilocybin dose (1 mg/kg) induced progressively lower HTR in heterozygous and homozygous knockout mice for serotonin 2A receptor (5HT2AR), compared to wild type. Synaptic increase of 5-HT by citalopram dose-dependently attenuated psilocybin-induced HTR after both acute and chronic dosing regimens. Conversely, depletion of 5-HT by p-chlorophenylalanine potentiated psilocybin-evoked HTR. Serotonin 1A receptor (5HT1AR) agonist 8-OH-DPAT dose-dependently decreased psilocybin-induced HTR, demonstrating functional interaction between 5HT2AR and 5HT1AR for psychedelic effects.</p><p><strong>Conclusions: </strong>The present findings reveal an inverse correlation between cortical 5-HT levels and the acute psychedelic-like effects of psilocybin. Consequently, the enhancement of serotonergic activity induced by prior antidepressant treatment may underlie interindividual variability in the acute response to psychedelics. Investigating these mechanisms in relation to the sustained therapeutic outcomes of psilocybin could contribute to optimizing the efficacy of psychedelic-based therapies.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activating group II metabotropic glutamate receptors in the basolateral amygdala inhibits increases in reward seeking triggered by discriminative stimuli in rats. 激活基底外侧杏仁核II组代谢性谷氨酸受体抑制大鼠鉴别刺激引发的奖赏寻求增加。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf030
Mandy Rita LeCocq, Amélie Mainville-Berthiaume, Isabel Laplante, Anne-Noël Samaha
{"title":"Activating group II metabotropic glutamate receptors in the basolateral amygdala inhibits increases in reward seeking triggered by discriminative stimuli in rats.","authors":"Mandy Rita LeCocq, Amélie Mainville-Berthiaume, Isabel Laplante, Anne-Noël Samaha","doi":"10.1093/ijnp/pyaf030","DOIUrl":"10.1093/ijnp/pyaf030","url":null,"abstract":"<p><strong>Background: </strong>Reward-associated cues guide reward-seeking behaviors. These cues include conditioned stimuli (CSs), which occur following seeking actions and predict reward delivery, and discriminative stimuli (DSs), which occur response-independently and signal that a seeking action will produce reward. Metabotropic group II glutamate (mGlu2/3) receptors in the basolateral amygdala (BLA) modulate CS-guided reward seeking; however, their role in DS effects is unknown.</p><p><strong>Methods: </strong>We developed a procedure to assess DS and CS effects on reward seeking in the same subjects within the same test session. Female and male rats self-administered sucrose where DSs signaled periods of sucrose availability (DS+) and unavailability (DS-). During DS+ trials, lever presses produced sucrose paired with a CS+. During DS- trials, lever presses produced a CS- and no sucrose. Across 14 sessions, rats learned to load up on sucrose during DS+ trials and inhibit responding during DS- trials. We then determined the effects of intra-BLA microinfusions of the mGlu2/3 receptor agonist LY379268 on cue-evoked sucrose seeking during a test where the DSs and CSs were presented response-independently, without sucrose. Before testing, rats received intra-BLA microinjections of artificial cerebrospinal fluid (aCSF) or LY379268.</p><p><strong>Results: </strong>Under aCSF, only the DS+ and DS+CS+ combination triggered increases in reward-seeking behavior. The CS+ alone was ineffective. Intra-BLA LY379268 suppressed the increases in sucrose seeking triggered by the DS+ and DS+CS+ combination.</p><p><strong>Conclusions: </strong>Using a new procedure to test reward seeking induced by DSs and CSs, we show that BLA mGlu2/3 receptor activity mediates the incentive motivational effects of reward-predictive DSs.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute effects of intranasal esketamine application on thalamic structures in healthy individuals. 鼻内应用艾氯胺酮对健康人丘脑结构的急性影响。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf037
Benjamin Spurny-Dworak, Thomas Liebe, Samantha Graf, Gregor Dörl, Peter Stöhrmann, Elisa Briem, Manfred Klöbl, Clemens Schmidt, Marie Spies, Rupert Lanzenberger
{"title":"Acute effects of intranasal esketamine application on thalamic structures in healthy individuals.","authors":"Benjamin Spurny-Dworak, Thomas Liebe, Samantha Graf, Gregor Dörl, Peter Stöhrmann, Elisa Briem, Manfred Klöbl, Clemens Schmidt, Marie Spies, Rupert Lanzenberger","doi":"10.1093/ijnp/pyaf037","DOIUrl":"10.1093/ijnp/pyaf037","url":null,"abstract":"<p><strong>Background: </strong>The N-methyl-D-aspartate receptor antagonist ketamine has found broad application in the field of psychiatry. Due to its rapid antidepressant and anti-suicidal properties, it is used as a treatment for major depressive disorder. Furthermore, ketamine evokes dissociative and psychotropic states, which allows the modeling of schizophrenic symptoms. The thalamus, a main target for ketamine's actions, consists of different nuclei responsible for sensory gating, attention, and consciousness. Thus, we here examine the effects of intranasally applied ketamine on thalamic structures in healthy individuals in a cross-over placebo-controlled study.</p><p><strong>Methods: </strong>Twenty-six subjects (14 female, mean age ± SD = 24.3 ± 3 years) underwent two magnetic resonance imaging scans on a 3T system immediately after receiving a subanesthetic dose of 56 mg esketamine (2x Spravato 28mg nasal sprays) or placebo in a cross-over study design. FreeSurfer was used for morphological analysis of the thalamus and its distinct nuclei based on derived T1-weighted MPRAGE images. Repeated measure analyses of covariance across the whole group, regardless of measurement order, and the subgroup, receiving placebo in the first scan, were performed for the thalamus and all its nuclei, for each hemisphere, separately. Post hoc tests on thalamic nuclei were done in an exploratory manner.</p><p><strong>Results: </strong>We found a significant volume increase in the right thalamus (pcorr. = .048), the pulvinar anterior nucleus (p = .048), and the right mediodorsal lateral parvocellular (p = .034) after esketamine in the subsample receiving placebo application in the first scan.</p><p><strong>Conclusion: </strong>Our results suggest rapid structural adaptations in right thalamic structures which serve as relay stations for the visual cortex. This emphasizes the thalamus' role in visual perception after esketamine and its importance as a target to model schizophrenic symptoms.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of hippocampal or thalamic inputs to the nucleus accumbens reverses stress-induced alterations in dopamine system function. 抑制海马或丘脑对伏隔核的输入可逆转应激诱导的多巴胺系统功能改变。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf034
Hannah B Elam, Alexandra M McCoy, Angela M Boley, Olivia J Yang, Natalie I Belle, Daniel J Lodge
{"title":"Inhibition of hippocampal or thalamic inputs to the nucleus accumbens reverses stress-induced alterations in dopamine system function.","authors":"Hannah B Elam, Alexandra M McCoy, Angela M Boley, Olivia J Yang, Natalie I Belle, Daniel J Lodge","doi":"10.1093/ijnp/pyaf034","DOIUrl":"10.1093/ijnp/pyaf034","url":null,"abstract":"<p><strong>Background: </strong>Symptoms of psychosis are often observed in patients with post-traumatic stress disorder (PTSD) and are driven by aberrant regulation of the mesolimbic dopamine system. We have previously shown that targeting upstream brain regions that regulate dopamine neuron activity, the ventral hippocampus (vHipp), and paraventricular nucleus of the thalamus (PVT) maybe a novel approach to restore dopamine system function. The vHipp and PVT work in concert to regulate ventral tegmental area (VTA) dopamine neuron activity through a multisynaptic circuit that begins with inputs to the nucleus accumbens (NAc). Therefore, we hypothesized that inhibition of projections from either the vHipp or PVT to the NAc would reverse stress-induced alterations in dopamine system function.</p><p><strong>Methods: </strong>In this study, we induced stress-related pathophysiology in rats using a 2-day inescapable foot shock procedure. We then examined if foot shock stress altered the firing patterns and coordinated neuronal activity within vHipp and PVT circuits. Finally, we examined if chemogenetic inhibition of NAc afferents could reverse stress-induced alterations in dopamine system function.</p><p><strong>Results: </strong>We observed a significant increase in coherence between the PVT and NAc up to 48 hours after foot shock stress. In addition, stress increased VTA dopamine neuron population activity, which was reversed following chemogenetic inhibition of either vHipp-NAc or PVT-NAc projections.</p><p><strong>Conclusions: </strong>Taken together, these results suggest that increased coherence between the PVT and NAc, following stress, may contribute to psychosis-like symptoms but targeting either the PVT or vHipp may be viable options for the treatment of comorbid psychosis related to PTSD.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. 艾氯胺酮治疗难治性抑郁症的安全性和有效性:长期扩展研究。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf027
Naim Zaki, Li Nancy Chen, Rosanne Lane, Teodora Doherty, Wayne C Drevets, Randall L Morrison, Gerard Sanacora, Samuel T Wilkinson, Allan H Young, Acioly L T Lacerda, Jong-Woo Paik, Vanina Popova, Dong-Jing Fu
{"title":"Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.","authors":"Naim Zaki, Li Nancy Chen, Rosanne Lane, Teodora Doherty, Wayne C Drevets, Randall L Morrison, Gerard Sanacora, Samuel T Wilkinson, Allan H Young, Acioly L T Lacerda, Jong-Woo Paik, Vanina Popova, Dong-Jing Fu","doi":"10.1093/ijnp/pyaf027","DOIUrl":"10.1093/ijnp/pyaf027","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;The rates of relapse and suicide risk are higher in treatment-resistant depression (TRD) vs non-treatment-resistant major depressive disorder. Even among patients with TRD who initially respond, the majority (70%) relapse within 6 months.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the long-term safety and efficacy of esketamine nasal spray, combined with an oral antidepressant, in patients with TRD.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Phase 3, open-label, single-arm long-term extension study (SUSTAIN-3) conducted from June 2016 to December 2022.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Outpatient.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Adults with TRD who participated in ≥1 of 6 phase 3 \"parent\" studies continued esketamine by either entering a 4-week induction phase followed by an optimization/maintenance phase of variable duration (n = 458) or directly entering the optimization/maintenance phase of SUSTAIN-3 (n = 690), based on their individual response to study drug at the endpoint of the parent study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Intranasal esketamine dosing was flexible, twice-weekly during induction and individualized to depression severity during optimization/maintenance (weekly, every-other-week, or every-4-weeks), under direct supervision by site staff.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;To assess the long-term safety of esketamine. Efficacy endpoints included the change in depressive symptoms, assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 1148 patients were enrolled. Total exposure to esketamine was 3777 cumulative patient-years. Mean (median, range) exposure to esketamine in SUSTAIN-3 was 42.9 (45.8, range 0-79) months. The most common adverse events were headache (36.9%), dizziness (33.9%), nausea (33.6%), dissociation (25.5%), nasopharyngitis (23.8%), somnolence (23.1%), dysgeusia (20.2%), and back pain (20.0%). During the study, 5.3% and 6.4% of participants discontinued due to lack of efficacy or adverse event, respectively. Nine participants died: COVID-19-related (n = 3), pneumonia (n = 2), and completed suicide, myocardial infarction, multiple injuries, unknown cause (n = 1 each). The mean MADRS total score decreased during induction, and this reduction persisted during optimization/maintenance (mean [SD] change from baseline-to-phase endpoint of each phase: induction: -12.8 [9.73]; optimization/maintenance: + 0.2 [9.93]). A total of 35.6% of participants were in remission at the induction endpoint, and 48.5% and 49.6% at week 112 and optimization/maintenance endpoint, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In the SUSTAIN-3 final dataset, no new safety signals were identified during long-term treatment with intermittently-dosed esketamine, combined with oral antidepressant, and improvement in depression generally persisted among participants who remained on maintenance treatment. These results add ","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia. 鲁哌酮单药治疗精神分裂症阴性症状。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf032
Michael Davidson, Nadine Noel, Florent Schmitt, Remy Luthringer
{"title":"Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia.","authors":"Michael Davidson, Nadine Noel, Florent Schmitt, Remy Luthringer","doi":"10.1093/ijnp/pyaf032","DOIUrl":"10.1093/ijnp/pyaf032","url":null,"abstract":"<p><p>Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. Roluperidone administered as monotherapy to patients suffering from mild to moderate negative symptoms and withdrawal from antipsychotic drugs, improved negative symptoms in 2 clinical trials. The patients who were symptomatically stable for 3 or 6 months before antipsychotic drug withdrawal showed a very low rate of psychotic symptoms worsening over 6 or 9-month trial duration. Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological modulation of directed network communication and neural hubs in action-effect integration. 定向网络通信和神经中枢在行动-效果整合中的药理调节。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf031
Jasmin Mayer, Anna Helin Koyun, Moritz Mückschel, Veit Roessner, Bernhard Hommel, Christian Beste
{"title":"Pharmacological modulation of directed network communication and neural hubs in action-effect integration.","authors":"Jasmin Mayer, Anna Helin Koyun, Moritz Mückschel, Veit Roessner, Bernhard Hommel, Christian Beste","doi":"10.1093/ijnp/pyaf031","DOIUrl":"10.1093/ijnp/pyaf031","url":null,"abstract":"<p><strong>Background: </strong>Acting intentionally requires individuals to anticipate the effects of their actions. Recent work has revealed the neural oscillatory dynamics underlying the establishment of action-effect bindings, which are vital to anticipating action effects. However, the neurobiological basis of these processes is elusive.</p><p><strong>Methods: </strong>Healthy adult participants (N = 54) engaged in a double-blind, counter-balanced, placebo-controlled experiment in which they worked in an experiment able to examine how action effects are planned, anticipated, and processed under placebo and methylphenidate conditions. Electroencephalogram data were analyzed to investigate the directed communication in cortical networks underlying action effect integration.</p><p><strong>Results: </strong>We show that an increase in catecholaminergic system activity alters the strength of directed communication in a cortical theta frequency network constituted by the insular cortex, the anterior temporal lobe, and the inferior frontal cortex. Additionally, pharmacological modulation regulates which of the brain structures act as a hub in different phases of the action-effect binding process.</p><p><strong>Conclusions: </strong>The findings highlight how the neural organization of processes supporting intentional action can be optimized neurobiologically through the catecholaminergic system.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular targets of vortioxetine mediating glioblastoma suppression revealed by gene and protein network analyses and molecular docking simulations. 沃替西汀介导胶质母细胞瘤抑制的分子靶点通过基因和蛋白质网络分析和分子对接模拟揭示。
IF 4.5 2区 医学
International Journal of Neuropsychopharmacology Pub Date : 2025-06-06 DOI: 10.1093/ijnp/pyaf029
Chuanjun Zhuo, Chao Li, Qiuyu Zhang, Lei Yang, Ying Zhang, Ximing Chen, Xiaoyan Ma, Ranli Li, Lina Wang, Hongjun Tian
{"title":"Molecular targets of vortioxetine mediating glioblastoma suppression revealed by gene and protein network analyses and molecular docking simulations.","authors":"Chuanjun Zhuo, Chao Li, Qiuyu Zhang, Lei Yang, Ying Zhang, Ximing Chen, Xiaoyan Ma, Ranli Li, Lina Wang, Hongjun Tian","doi":"10.1093/ijnp/pyaf029","DOIUrl":"10.1093/ijnp/pyaf029","url":null,"abstract":"<p><strong>Background: </strong>Vortioxetine is a serotonin reuptake inhibitor and serotonin receptor modulator used for the treatment of major depressive disorder, but recent studies have also reported anticancer effects in models of glioblastoma. Given the well-established benefits of drug repositioning, we examined the pharmacological mechanism for these anticancer actions using bioinformatics and molecular docking.</p><p><strong>Methods: </strong>Putative molecular targets for vortioxetine were identified by searching DrugBank, GeneCards, SwissTargetPrediction, Comparative Toxicogenomics Database, and SuperPred databases, while glioblastoma-related proteins were identified using GeneCards, Online Mendelian Inheritance in Man; , and Therapeutic Target Database . A protein-protein interaction (PPI) network was constructed from vortioxetine targets also involved in glioblastoma to identify core (hub) targets, which were then characterized by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses using database for annotation, visualization, and integrated discovery. Cytoscape was utilized to generate a drug-pathway-target-disease network, and molecular docking simulations were performed to evaluate direct interactions between vortioxetine and core target proteins.</p><p><strong>Results: </strong>A total of 234 unique vortioxetine protein targets were identified. Among 234 vortioxetine targets identified, 48 were also related to glioblastoma. Topological analysis of the PPI network revealed 5 core targets: the serine/threonine kinase AKT1, transcription factor hypoxia-inducible factor (HIF)-1, cell adhesion molecule cadherin-E, NF-κB subunit p105, and prostaglandin-endoperoxide synthase 2. According to GO and KEGG pathway analyses, the anticancer efficacy of vortioxetine may be mediated by effects on glucose metabolism, cell migration, phosphorylation, inflammatory responses, apoptosis, and signaling via Rap1, chemical carcinogenesis-reactive oxygen species, and HIF-1. Molecular docking revealed moderately strong affinities between vortioxetine and 4 core targets.</p><p><strong>Conclusions: </strong>This study suggests that vortioxetine may inhibit glioblastoma development through direct effects on multiple targets and further emphasizes the value of bioinformatics analyses for drug repositioning.</p>","PeriodicalId":14134,"journal":{"name":"International Journal of Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信